Taro Pharmaceutical Industries (NYSE:TARO) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Taro Pharmaceutical Industries (NYSE:TAROGet Free Report) in a report released on Wednesday. The brokerage set a “strong-buy” rating on the stock.

Separately, HC Wainwright downgraded shares of Taro Pharmaceutical Industries from a “buy” rating to a “neutral” rating and set a $43.00 price target for the company. in a research report on Thursday, January 18th.

Read Our Latest Stock Analysis on Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Stock Down 0.2 %

TARO opened at $42.13 on Wednesday. Taro Pharmaceutical Industries has a twelve month low of $23.92 and a twelve month high of $45.76. The company has a 50-day moving average price of $42.29 and a 200 day moving average price of $39.47. The company has a market cap of $1.58 billion, a PE ratio of 34.53 and a beta of 0.61.

Taro Pharmaceutical Industries (NYSE:TAROGet Free Report) last released its quarterly earnings results on Thursday, January 25th. The company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.30 by $0.26. Taro Pharmaceutical Industries had a net margin of 7.48% and a return on equity of 3.26%. The firm had revenue of $157.15 million during the quarter, compared to the consensus estimate of $154.90 million. As a group, sell-side analysts expect that Taro Pharmaceutical Industries will post 1.38 earnings per share for the current year.

Institutional Trading of Taro Pharmaceutical Industries

Hedge funds have recently bought and sold shares of the business. Harvest Management LLC grew its stake in shares of Taro Pharmaceutical Industries by 3.9% in the 4th quarter. Harvest Management LLC now owns 7,380 shares of the company’s stock valued at $308,000 after buying an additional 274 shares during the period. Bank of New York Mellon Corp grew its stake in shares of Taro Pharmaceutical Industries by 1.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 22,223 shares of the company’s stock valued at $838,000 after buying an additional 307 shares during the period. Legal & General Group Plc grew its stake in shares of Taro Pharmaceutical Industries by 5.3% in the 4th quarter. Legal & General Group Plc now owns 6,732 shares of the company’s stock valued at $195,000 after buying an additional 339 shares during the period. UBS Group AG grew its stake in shares of Taro Pharmaceutical Industries by 71.6% in the 2nd quarter. UBS Group AG now owns 925 shares of the company’s stock valued at $34,000 after buying an additional 386 shares during the period. Finally, Swiss National Bank grew its stake in shares of Taro Pharmaceutical Industries by 2.0% in the 2nd quarter. Swiss National Bank now owns 20,900 shares of the company’s stock valued at $793,000 after buying an additional 400 shares during the period. Institutional investors and hedge funds own 91.40% of the company’s stock.

About Taro Pharmaceutical Industries

(Get Free Report)

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products.

Featured Articles

Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.